seems to have met the primary end points. Any ideas on whether this could be of any challenge to erivedge??
It's hard to know. NVS called the trial a pivotal P2. This is usually used when despite being a P2, the trial could be sufficient for a submission, which would put it on the market next year.
BUT, there are a few big open questions.
A) The trial could well be a "success" but not enough for a submission.
B) If they were looking at an accelerated approval, erivedge could have changed the picture (as now patients do have an option).
So I would wait until NVS discusses this, don't know when.
ok thats good. I did not get to read much about it. it is now at Ph1? or Ph2?
I certainly hope not, we just started to see growth in sales.
I am hoping too.